1. Introduction {#sec1-jcm-09-00414}
===============

Community-acquired pneumonia (CAP) and cardiovascular (CV) disease are two major public health issues. CAP alone results in 1.7 million hospital admissions and almost 50,000 deaths every year in the USA \[[@B1-jcm-09-00414],[@B2-jcm-09-00414]\], with a similar adjusted incidence observed in Europe \[[@B3-jcm-09-00414],[@B4-jcm-09-00414]\]. In developed countries, CV disease is the leading cause of morbidity and mortality. Together, these conditions weigh heavily on national health systems and efforts to mitigate their global burden should be a priority for policy makers \[[@B5-jcm-09-00414]\].

Although seemingly unrelated beforehand, the interplay between CAP and acute CV events has been elucidated in the last decades \[[@B6-jcm-09-00414]\]. Myocardial infarction, heart failure, arrhythmias and stroke were witnessed to increase following a CAP episode \[[@B7-jcm-09-00414]\]. The risk is maximal during the acute phase but persists in time after the infection has abated \[[@B8-jcm-09-00414]\]. Moreover, a higher likelihood of a poorer outcome in a patient with CAP complicated by a CV event exists when compared to one with an uncomplicated course \[[@B7-jcm-09-00414]\]. At the population level, the practical implications of such an association are immense. The widespread use of influenza and pneumococcal vaccination is an attractive option. When considering treatment possibilities, drugs with proven efficacy in the CV arena could theoretically be initiated to modulate outcomes, both acutely but also in the context of long-term CV prevention. Definite evidence-based guidance on how to perform these interventions at a patient level is, however, lacking.

In this article, we provide a broadened description of the current evidence associating CAP and acute CV disease. From bench to bedside, we begin with mechanistic links of the pathophysiologic repercussion of CAP on the cardiovascular system, proceed to an updated systematic review of and meta-analysis of observational clinical studies and end with the impact of potential interventions and future avenues of research.

2. Materials and Methods {#sec2-jcm-09-00414}
========================

2.1. Search Strategy {#sec2dot1-jcm-09-00414}
--------------------

We searched Medline from inception to 1 November 2019 for articles in English, French, Spanish, and Portuguese languages evaluating the incidence of subsequent CV events after a first CAP episode (community-acquired pneumonia" AND ("complications" OR "acute coronary syndromes" OR "myocardial infarction" OR "heart failure" OR "arrhythmia" OR "atrial fibrillation" OR "stroke"). To ensure the completeness of our review, we also retrieved previously published reviews on the subject and scanned their references for any additional missed publications in the primary search.

2.2. Population and Outcomes {#sec2dot2-jcm-09-00414}
----------------------------

We restricted our search to adult non-immunocompromised patients with clinical and radiological evidence of CAP (as a means to improve specificity) for whom outcomes were explicitly reported in the methods section. Consecutive enrolment of patients and the quantification of CV events in the entire cohort were also prerequisites for inclusion. Studies focusing on nosocomial or health care--associated pneumonia, antibiotic efficacy trials (due to selection bias) and articles dealing primarily with pediatric patients or patients infected with the human immunodeficiency virus were excluded.

If assessed, independent predictors for CV complications after CAP were collected and tabulated. To minimize the influence of patient heterogeneity in the estimation of effect sizes, we stratified patients according to treatment setting and clinical severity, when available. Patients initially treated in an ambulatory setting were defined as outpatients while patients admitted to a hospital on presentation were considered as inpatients. High risk patients were defined as having a pneumonia severity index (PSI) class IV or V or and/or requiring admission to the intensive care unit (ICU). Cardiovascular events were categorized as overall cardiac complications, acute coronary syndromes, new or worsening heart failure, and new or worsened arrhythmia and stroke. We collected data on all-cause mortality occurring either during hospital admission on during the first 30 to 90 days.

2.3. Study Selection, Data Extraction and Synthesis {#sec2dot3-jcm-09-00414}
---------------------------------------------------

After the initial search, the first author extracted all abstracts, excluded irrelevant studies and if deemed adequate, proceeded to full-text reading and data tabulation. Study flowchart is depicted in [Figure 1](#jcm-09-00414-f001){ref-type="fig"}. The methodologic quality of available studies was graded according to Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines ([Supplementary Table S1](#app1-jcm-09-00414){ref-type="app"}).

2.4. Statistical Analysis {#sec2dot4-jcm-09-00414}
-------------------------

In contrast to a traditional meta-analysis aiming to describe an effect size related to a therapeutic intervention, a meta-analysis of proportions has the goal of obtaining a more precise estimate of the overall proportion for a certain case or event \[[@B9-jcm-09-00414]\]. In order to achieve this, raw proportional data need to be conformed to the normal distribution by employing one of several validated statistical approaches. We chose Freeman and Tukey's double-arcsine transformation, a method which stabilizes study variance and reduces the probability of inaccurate weighting of each study when the inverse of the variance of the transformed proportion is used as a study weight \[[@B10-jcm-09-00414]\]. To further minimize population differences between studies, patient cohorts were divided by event category, setting, and clinical severity before estimating pooled event rates using a random-effects model.

We anticipated that the identification of more studies spanning the eight-year time frame after the last published systematic review would justify an analysis by year of publication. Therefore, a meta-regression using year of publication as a moderator variable was undertaken. To predict the effect of a hypothesized moderator, a weighted linear regression model was performed, in which the effect sizes (i.e., transformed proportions of CV events) are regressed onto the moderator, and a linear equation obtained. Finally, we assessed for publication bias by funnel plot inspection \[[@B11-jcm-09-00414]\] and formally by Egger's test \[[@B12-jcm-09-00414]\]. In a funnel plot, each study is inscribed around the summary effect size (a vertical line) bounded by two converging slopes defining the 95% confidence interval around it. Imprecision is decrementally displayed on the y-axis and is zero at the triangle vertex. Absence of bias would result in a perfectly symmetrical plot. All analysis were performed using R (version 3.6.1, Vienna, Austria).

3. Results {#sec3-jcm-09-00414}
==========

3.1. Basic Science and Clinical Insights Associating CAP to CV Events {#sec3dot1-jcm-09-00414}
---------------------------------------------------------------------

### 3.1.1. Coronary Arteries and Myocardial Infarction {#sec3dot1dot1-jcm-09-00414}

Theoretically, three different mechanisms prompted by pneumonia can contribute to a coronary event: (1) plaque rupture or fissuring leading to superimposed thrombus formation and cardiac troponin rise and/or fall, corresponding to type 1 myocardial infarction (MI); (2) type 2 MI, due to an imbalance between oxygen delivery and consumption in the myocardium, together with ischemic symptoms, especially if fixed stenoses are present, and (3) "myocardial injury", when a troponin leak is detected without evidence of ischemia \[[@B13-jcm-09-00414]\]. The most accepted and important pathway involves inflammation driven plaque instability \[[@B14-jcm-09-00414]\]. By experimentally inducing sepsis in animal models, investigators have found post-mortem pathologic proof of atheromata growth and vascular inflammation. In mice fed with an atherogenic diet and subsequently developing provoked secondary fecal peritonitis, Kaynar et al. found increased abdominal aorta atheroma size, plaque neutrophil count and circulating proinflammatory cytokines versus a sham procedure, all persisting five months after the index intervention \[[@B15-jcm-09-00414]\]. In humans, similarities are quite striking. In a post-mortem study, Mauriello et al. performed a detailed histologic analysis of coronary segments of sixteen patients who died after acute MI and compared them with controls who died of non-cardiac causes and had either stable angina or no CAD suspicion \[[@B16-jcm-09-00414]\]. Significantly increased inflammatory infiltrates (macrophage and T-lymphocyte) were noticed not only in the culprit lesion but also in non-culprit vulnerable plaques and stable plaques in MI patients, suggesting underlying inflammation of the entire coronary tree even without sepsis. In another small sized study, fourteen patients who died from systemic infection (six of which with either upper or lower respiratory tract infection) were found to have more leucocytes in both plaque and adventitia than controls \[[@B17-jcm-09-00414]\]. Inflammation that persists after the acute infectious episode could be causally linked increased mortality witnessed after hospital discharge following CAP \[[@B6-jcm-09-00414]\].

Other proposed pathophysiologic pathways include hypercoagulability and hampered vascular tone. A significant proportion of pneumonia patients exhibited increased levels of coagulation markers in a study by Milbrandt et al, which persisted up to a week after hospital admission and were associated with increased mortality \[[@B18-jcm-09-00414]\]. Although coronary perfusion is preserved or even increased in human septic shock \[[@B19-jcm-09-00414]\], vasomotor disturbances resulting from changes in vasoactive mediators and capable of compromising myocardial oxygen delivery have been reported in animal \[[@B20-jcm-09-00414]\] studies and could play a role in severe Gram positive infections.

### 3.1.2. Myocardium and Heart Failure {#sec3dot1dot2-jcm-09-00414}

Direct myocardial involvement by pathogens has been shown for viral and bacterial myocarditis caused mainly by influenza virus, adenovirus, respiratory syncytial virus and enterovirus but also bacteria including *Streptococcus pneumoniae*, *Chlamydophila pneumoniae*, *Mycoplasma pneumoniae*, *Staphylococcus aureus* and *Legionella* spp. \[[@B7-jcm-09-00414]\]. Molecular studies have further suggested that up to a third of CAP cases in adults result from viral infection \[[@B7-jcm-09-00414]\]. Kotaka et al. demonstrated that influenza virus inoculation in a murine model led to cytotoxic effect in cardiomyocytes and coronary thrombosis \[[@B21-jcm-09-00414]\]. In the human heart, necropsy studies have similarly revealed edema, sarcomeric disarray and viral particle isolation from fatal influenza infection. Following invasive pneumococcal disease, Brown et al. disclosed for the first time how *Streptococcus pneumoniae* translocates into the myocardium of primates and patients who succumbed to CAP \[[@B22-jcm-09-00414]\]. In their study, microlesions containing bacteria were described inside cardiomyocytes, which if treated with antibiotics led to local inflammation and scarring. The authors speculate that these foci may generate future myocardial dysfunction or cardiac arrhythmias.

### 3.1.3. Cardiac Rhythm Disturbances {#sec3dot1dot3-jcm-09-00414}

Atrial fibrillation is the most common sustained arrhythmia encountered in clinical practice \[[@B23-jcm-09-00414]\]. Known transient risk factors include fever, hypoxia and hemodynamic disturbances, all of which can be triggered by infections including pneumonia \[[@B24-jcm-09-00414]\]. An increased incidence in AF as well as other specified arrhythmias following CAP is a phenomenon well described in the literature. In a study conducted in critically ill patients, sepsis and acute respiratory failure were the most powerful predictors of AF onset \[[@B25-jcm-09-00414]\]. Proposed mechanisms include direct toxic effect on the cardiac electric system, augmented loading imposed on cardiomyocytes, inflammation, sympathetic hyperactivity, ischemia and pharmacological agents, including antibiotics. AF occurrence is associated with worse short and long term outcomes in patients with infections \[[@B26-jcm-09-00414],[@B27-jcm-09-00414]\], directly influencing patient management, namely the decision to initiate anticoagulation, and conditioning rhythm or rate control strategies.

3.2. Clinical Studies of Short Term Incident Acute CV Disease after CAP {#sec3dot2-jcm-09-00414}
-----------------------------------------------------------------------

We found 39 studies ([Table 1](#jcm-09-00414-t001){ref-type="table"}, see also [Supplementary Table S2](#app1-jcm-09-00414){ref-type="app"} for detailed study description) reporting the incidence of CV events following CAP. Retrieved studies spanned a thirty-five-year period and included mostly North American patients. The mean weighted age of patients was 72 ± 11 years and most were male (79%).

### 3.2.1. Overall Cardiac Complications {#sec3dot2dot1-jcm-09-00414}

Twelve studies provided data on inpatients \[[@B31-jcm-09-00414],[@B39-jcm-09-00414],[@B40-jcm-09-00414],[@B46-jcm-09-00414],[@B47-jcm-09-00414],[@B48-jcm-09-00414],[@B54-jcm-09-00414],[@B56-jcm-09-00414],[@B58-jcm-09-00414],[@B59-jcm-09-00414],[@B64-jcm-09-00414]\], four on low-risk inpatients \[[@B45-jcm-09-00414],[@B55-jcm-09-00414],[@B57-jcm-09-00414],[@B61-jcm-09-00414]\] and five on high-risk inpatients \[[@B35-jcm-09-00414],[@B55-jcm-09-00414],[@B57-jcm-09-00414],[@B61-jcm-09-00414],[@B63-jcm-09-00414]\]. Pooled event rates were 13.9% (95% confidence interval (CI) 9.6--18.9), 5.7% (95% CI 3.1--9.0) and 15.6% (95% CI 6.1--28.4), respectively ([Figure 2](#jcm-09-00414-f002){ref-type="fig"}).

### 3.2.2. Acute Coronary Syndromes {#sec3dot2dot2-jcm-09-00414}

Thirteen studies reported data on inpatients \[[@B48-jcm-09-00414],[@B49-jcm-09-00414],[@B50-jcm-09-00414],[@B51-jcm-09-00414],[@B52-jcm-09-00414],[@B53-jcm-09-00414],[@B54-jcm-09-00414],[@B55-jcm-09-00414],[@B56-jcm-09-00414],[@B58-jcm-09-00414],[@B60-jcm-09-00414],[@B61-jcm-09-00414],[@B64-jcm-09-00414]\], two on low-risk patients \[[@B44-jcm-09-00414],[@B57-jcm-09-00414]\] and high-risk \[[@B57-jcm-09-00414],[@B63-jcm-09-00414]\] patients and one on outpatients \[[@B54-jcm-09-00414]\]. Pooled event rates were 4.5% (95% CI 2.9--6.5), 0.2 (95% CI 0--0.7), 1.6 (95% CI 0.1--4.9), and 0.9 (95% CI 0.5--1.8), respectively ([Figure 3](#jcm-09-00414-f003){ref-type="fig"}).

### 3.2.3. Heart Failure {#sec3dot2dot3-jcm-09-00414}

Sixteen studies included inpatients \[[@B29-jcm-09-00414],[@B30-jcm-09-00414],[@B36-jcm-09-00414],[@B37-jcm-09-00414],[@B38-jcm-09-00414],[@B47-jcm-09-00414],[@B48-jcm-09-00414],[@B50-jcm-09-00414],[@B53-jcm-09-00414],[@B54-jcm-09-00414],[@B55-jcm-09-00414],[@B56-jcm-09-00414],[@B57-jcm-09-00414],[@B61-jcm-09-00414],[@B62-jcm-09-00414],[@B64-jcm-09-00414]\], three focused on low-risk patients \[[@B41-jcm-09-00414],[@B42-jcm-09-00414],[@B44-jcm-09-00414]\], two focused on high-risk patients \[[@B43-jcm-09-00414],[@B63-jcm-09-00414]\], and two on outpatients \[[@B54-jcm-09-00414],[@B62-jcm-09-00414]\]. Pooled event rates were 9.2% (95% CI 6.7--12.2), 5.6% (95% CI 1.5--11.9), 11.1% (95% CI% 0--39), and 1.0% (95% CI 0.6--1.6), respectively ([Figure 4](#jcm-09-00414-f004){ref-type="fig"}).

### 3.2.4. Arrhythmias {#sec3dot2dot4-jcm-09-00414}

Incident arrhythmias were mentioned in twenty studies. Seventeen studies analysed inpatients \[[@B28-jcm-09-00414],[@B32-jcm-09-00414],[@B34-jcm-09-00414],[@B47-jcm-09-00414],[@B48-jcm-09-00414],[@B50-jcm-09-00414],[@B52-jcm-09-00414],[@B53-jcm-09-00414],[@B54-jcm-09-00414],[@B55-jcm-09-00414],[@B56-jcm-09-00414],[@B57-jcm-09-00414],[@B58-jcm-09-00414],[@B61-jcm-09-00414],[@B64-jcm-09-00414],[@B65-jcm-09-00414],[@B66-jcm-09-00414]\], two focused on high-risk inpatients \[[@B43-jcm-09-00414],[@B63-jcm-09-00414]\] and one on outpatients \[[@B54-jcm-09-00414]\]. Pooled event rates were 7.2% (95% CI 5.6--9.0), 12.7% (95% CI 9.8--15.8), and 0.7% (95% CI 0.3--1.5), respectively ([Figure 5](#jcm-09-00414-f005){ref-type="fig"}).

### 3.2.5. Stroke {#sec3dot2dot5-jcm-09-00414}

New-onset stroke following CAP was reported in four studies \[[@B52-jcm-09-00414],[@B57-jcm-09-00414],[@B61-jcm-09-00414],[@B63-jcm-09-00414]\], all on inpatients. Pooled event rate was 1.7% (95% CI 1.0--2.6; [Figure 6](#jcm-09-00414-f006){ref-type="fig"}).

### 3.2.6. Meta-Regression Analysis and Publication Bias Assessment {#sec3dot2dot6-jcm-09-00414}

Meta-regression analysis ([Figure 7](#jcm-09-00414-f007){ref-type="fig"}) by study year revealed a decrease both in the overall proportion of cardiac complications and also individually when each complication was considered separately, more notably for incident heart failure. Funnel plot analysis and Egger's test showed significant asymmetry for overall cardiac complications only (z = −3.7562, *p* = 0.0002; [Supplementary File S1](#app1-jcm-09-00414){ref-type="app"}).

3.3. Risk Factors and Impact of Cardiac Complications on CAP Outcomes {#sec3dot3-jcm-09-00414}
---------------------------------------------------------------------

Risk factors for the occurrence of CV events were reported in thirteen studies \[[@B51-jcm-09-00414],[@B52-jcm-09-00414],[@B53-jcm-09-00414],[@B54-jcm-09-00414],[@B55-jcm-09-00414],[@B56-jcm-09-00414],[@B57-jcm-09-00414],[@B58-jcm-09-00414],[@B61-jcm-09-00414],[@B63-jcm-09-00414],[@B64-jcm-09-00414],[@B65-jcm-09-00414],[@B66-jcm-09-00414]\]. After adjustment for covariates, several clinical, microbiologic, laboratory, and imaging features were found to be independent predictors of an adverse CV event ([Table 2](#jcm-09-00414-t002){ref-type="table"}).

Seven studies evaluated whether CV events were independently associated with mortality in CAP patients \[[@B52-jcm-09-00414],[@B54-jcm-09-00414],[@B55-jcm-09-00414],[@B57-jcm-09-00414],[@B58-jcm-09-00414],[@B61-jcm-09-00414],[@B63-jcm-09-00414]\]. Multivariate analysis and propensity score matching were used to correct for confounders when assessing the impact of composite and individual CV events. Both overall and individual cardiac complications were associated with increased mortality after CAP ([Table 3](#jcm-09-00414-t003){ref-type="table"}).

3.4. Long Tterm Outcomes after CAP {#sec3dot4-jcm-09-00414}
----------------------------------

Soon after the onset of infection, a plateau of maximum risk for CV events is reached and persists for the following 30 days \[[@B67-jcm-09-00414]\]. Afterwards, it does not fall abruptly but gradually diminishes, conferring a long term increased risk that goes well beyond the acute phase \[[@B67-jcm-09-00414]\]. By retrospectively analysing data from two large observational cohorts of patients without known CV disease, Corrales-Medina et al. have estimated almost a doubling of CV events during a ten-year period when compared to controls \[[@B59-jcm-09-00414]\].

3.5. What Is the Role of Pharmacological Therapies? {#sec3dot5-jcm-09-00414}
---------------------------------------------------

Multiple investigators aimed to establish a role for CV and immunomodulating drug therapies in CAP patients. Below, we enumerate pharmacological classes and summarize the available evidence for their potential use in CAP.

### 3.5.1. Antiplatelet Drugs {#sec3dot5dot1-jcm-09-00414}

Different receptor pathways serve as potential targets for antiplatelet agents: (1) inhibitors of thromboxane A2 production (aspirin, triflusal), (2) antagonists of adenosine diphosphate (ADP)-activated P2Y~12~ receptors (ticlopidine, clopidogrel, prasugrel, ticagrelor, cangrelor), (3) antagonists of thrombin-activated proteinase activated receptor 1 (vorapaxar), and (4) GPIIb/IIIa inhibitors (abciximab, tirofiban, eptifibatide). Conflicting evidence regarding the role of aspirin in primary prevention led to the publication of two large scale randomized clinical trials who failed to demonstrate the benefit of aspirin in unselected patients without a previous CV event \[[@B68-jcm-09-00414],[@B69-jcm-09-00414]\]. To make matters worse, a signal toward increased bleeding was detected, leaving no compelling evidence for the chronic blocking of platelet cyclooxygenase beyond secondary prevention. In CAP patients, two prospective propensity matched studies showed that aspirin may be associated with decreased CV events \[[@B70-jcm-09-00414],[@B71-jcm-09-00414]\]. Recently, ticagrelor, a reversible P2Y~12~ platelet ADP receptor inhibitor, showed to decrease leukocyte adherent platelets and inflammatory markers in a small double-blinded trial in CAP \[[@B72-jcm-09-00414]\]. Patients randomized to ticagrelor had faster amelioration of oxygenation deficit and a trend towards better progression in lung function test results. Although using an antiplatelet agent in the acute setting might seem appealing based on heightened inflammation during CAP, this hypothesis remains to be adequately tested in a powered randomized trial and cannot therefore be recommended.

### 3.5.2. Statins and Other Lipid Lowering Agents {#sec3dot5dot2-jcm-09-00414}

Impeding cholesterol synthesis is perhaps the most effective drug intervention to reduce the incidence of de novo and recurring CV events. Data from more that 170,000 patients have demonstrated a significant impact of statin therapy in all-cause mortality, CV mortality and CV events, with a reassuring safety profile, in both primary and secondary prevention settings \[[@B73-jcm-09-00414]\]. In vitro and observational studies led to the belief that reducing inflammation through statins non-lipid lowering effects could translate into a similar benefit in sepsis, an hypothesis not confirmed in subsequent randomized trials \[[@B74-jcm-09-00414]\]. Specifically, trials that tested statins in ventilator associated pneumonia \[[@B75-jcm-09-00414]\] or acute respiratory distress syndrome \[[@B76-jcm-09-00414]\] have not proved to be better than placebo, leaving no convincing role for their use in this setting. The need for a prolonged exposure to statins in order to obtain clinical benefit might be an explanation to justify failure to improve outcomes. Recently, two other lipid lowering drugs (evolocumab, alirocumab) acting through inhibition of PCSK9 (proproteine convertase subtilisin/kexin type 9, a protein that targets low-density lipoprotein receptors for degradation in the liver) achieved event reduction on top of statin therapy \[[@B77-jcm-09-00414],[@B78-jcm-09-00414]\]. There are currently no published human studies exploring a potential effect of this new class of molecules on infection related outcomes. In an animal model, Berger et al. did not show a reduction of lipopolysaccharide induced mortality with the administration of anti-PCSK9 antibodies \[[@B79-jcm-09-00414]\].

### 3.5.3. Beta-Blockers, Angiotensin-Converting Enzyme Inhibitors (ACEi) and Angiotensin Receptor Blockers (ARB) {#sec3dot5dot3-jcm-09-00414}

Given their established role in CV disease treatment, investigators have explored a possible benefit of other cardioprotective drugs in CAP patients. Wu et al. employed multilevel regression modeling to examine the association between CV drug classes and either mortality or CV events \[[@B80-jcm-09-00414]\]. They found that while ACEi and ARBs were associated with decreased mortality, there was no significant association with decreased CV events. These results suggest that this decreased mortality is unlikely due to their potential cardioprotective effects. Higher quality studies are needed to confirm or refute this unexpected benefit.

### 3.5.4. Corticosteroids {#sec3dot5dot4-jcm-09-00414}

Corticosteroids have been tested in a wide spectrum of infectious diseases, yielding controversial results. In CAP, one large patient level meta-analysis \[[@B81-jcm-09-00414]\] pointed to a mortality benefit (34% relative risk reduction), while in another meta-analysis \[[@B82-jcm-09-00414]\] a very similar absolute reduction reached statistical significance with one of two random-effects models. In both studies, shorter length of stay (\~1 day) and more hyperglycemic episodes were noted. In the analysis of Briel et al., steroids were associated with an increased incidence of CAP related readmissions for various reasons including CV events. Recently, Cangemi et al. found that using corticosteroids for CAP halved the incident of intra-hospital MI, albeit not reducing either all-cause or CV mortality \[[@B83-jcm-09-00414]\].

### 3.5.5. Novel Drugs {#sec3dot5dot5-jcm-09-00414}

Canakinumab, a fully human monoclonal antibody targeting 1L-ß interleukin demonstrated a reduction in recurrent CV events in a randomized clinical trial against placebo \[[@B84-jcm-09-00414]\]. Conversely, the drug was associated with a small but significant increase of fatal infection or sepsis. Pneumonia rates were similar in both treatment arms.

3.6. Vaccination {#sec3dot6-jcm-09-00414}
----------------

Observational studies and secondary post-hoc analysis of large trials in CV disease have hinted towards a prognostic impact of influenza and pneumococcal vaccination, particularly in coronary artery disease related outcomes \[[@B85-jcm-09-00414]\]. In a meta-analysis of five randomized trials, influenza vaccination was associated with a 36% relative risk reduction in the incidence of major adverse cardiovascular events during a 12-month period, with no influence in mortality \[[@B86-jcm-09-00414]\]. Patients who had a recent ACS seemed to derive the largest benefit (55% relative risk reduction). Inferior quality evidence exists for pneumococcal vaccination. A meta-analysis of observational studies by Ren et al. revealed a 23% reduction in ACS in patients aged 65 or above \[[@B87-jcm-09-00414]\]. The benefit was lost when all patients were considered and was not extensible to other vascular territories. In the heart failure population, a signal towards a reduction in a composite endpoint of CV mortality and HF hospitalization in propensity matched influenza-vaccinated patients from a large trial was identified \[[@B88-jcm-09-00414]\]. There are presently no studies specifically addressing the effect of pneumococcal immunisation in HF patients.

3.7. Effects of Antibiotics on the Cardiovascular System {#sec3dot7-jcm-09-00414}
--------------------------------------------------------

While decisive to improve outcomes in patients with CAP, antibiotics are not free from toxicity, which may include the CV system. Although possessing useful anti-inflammatory properties, macrolides have been ascribed an increased risk in arrhythmic events and sudden cardiac death (SCD) through QT interval prolongation and polymorphic ventricular tachycardia facilitation. For azithromycin, the absolute risk was estimated to be an additional 47 deaths per one million five-day courses of therapy (all indications considered) when compared to amoxicillin \[[@B89-jcm-09-00414]\]. In a smaller propensity score matching study, Schembri et al. also found an independent association between clarithromycin use for CAP and CV events during a one-year follow-up (HR 1.68, 95% CI 1.18--2.38), which was not extensible to increased mortality \[[@B90-jcm-09-00414]\].

4. Discussion {#sec4-jcm-09-00414}
=============

By analysing epidemiologic data from more than a quarter billion individuals, Collins found an excess all-cause mortality accompanying a pairwise increase in influenza and pneumonia related fatalities during successive early 20^th^ century infection outbreaks \[[@B91-jcm-09-00414]\]. After this seminal report, a burgeoning number of observational studies and reviews has strengthened this association \[[@B92-jcm-09-00414],[@B93-jcm-09-00414],[@B94-jcm-09-00414],[@B95-jcm-09-00414],[@B96-jcm-09-00414]\]. Our updated systematic review and meta-analysis, encompassing 92,188 patients, the overwhelming majority (95%) treated as inpatients, further emphasizes the burden of incident CV disease following CAP. After pooling individual study rates, we found an incidence of overall cardiac complications of 13.9%. The most frequent cardiac complication in inpatients who were not stratified by severity was de novo or worsening heart failure in 9.2% of patients, 7.2% new-onset or worsening arrhythmias, and ACS in 4.5%. Stroke was the least common CV event in CAP patients.

The present review accrues data from fourteen more additional studies (\~75,000 patients) to the last review by Corrales-Medina et al. \[[@B97-jcm-09-00414]\], allowing us to perform a supplementary meta-regression moderated by study year. Globally and individually, the incidence of acute CV events following CAP seems to be decreasing, albeit slightly. These findings seem to be in line with reported rates of CV events in the non-CAP population, with the exception of atrial fibrillation. Yearly trends in acute myocardial infarction show that hospital admission is decreasing in both the US and in Europe \[[@B5-jcm-09-00414],[@B98-jcm-09-00414]\]. This may reflect the improved utilization of protective CV medication in the context of better primary care based prevention including pneumococcal and influenza immunization, along with improved secondary prevention after ACS. For heart failure, statistics indicate that the incidence is diminishing, at the expense of increased prevalence, which can be attributed to demographic shifts, improved quality of care, medical therapy and handling of comorbidities \[[@B99-jcm-09-00414]\]. Finally, regarding atrial fibrillation, data published by Schnabel et al. suggest that both its incidence and prevalence are increasing \[[@B100-jcm-09-00414]\]. In our study, the influence of considering all arrhythmias might have contributed to this apparent discrepancy.

After incorporating more recent studies, the list of independent predictors for cardiac complications is now longer and more complex. The range of predisposing factors includes host (CV and non-CV comorbidities) and pathogen-related features. Whilst the baseline comorbidities may share the same approach and in a way merely denote a sicker patient, different microbes may pose an opportunity for influencing patient outcomes by improving time to diagnosis and starting pathogen specific interventions. For pneumococcal pneumonia, bacterial exotoxin pneumolysin has been identified as key effector of cell and organ damage in murine models \[[@B101-jcm-09-00414],[@B102-jcm-09-00414]\] and could theoretically become a target for macrolides (or macrolide-like antibiotics), statins or cholesterol rich liposomes \[[@B103-jcm-09-00414]\]. If influenza is being considered, prompt detection may allow the early initiation of neuraminidase inhibitors. Not surprisingly, if a CV event supervenes after CAP, patients will likely fare worse. Our aggregated data from eight studies suggests an up to five-fold increase in mortality, mostly for compiled cardiac complications but also for individual events. Despite its observational nature, this signal is consistent between studies and possesses biological credibility, anticipating the likely presence of a true effect.

Notwithstanding the strengths provided by the increased number of studies included and a clearer view on the temporal trends in CV events after CAP in our updated review and meta-analysis, some limitations have to be acknowledged. Population heterogeneity, different causal pathogens, asymmetries in study design and imprecise event definitions may be responsible for the observed between study variance and wide confidence intervals around the measured effect, reducing the accuracy estimates of the real effect. Funnel plot analysis is in agreement with such wide dispersion of data. For heart failure, the interpretation of results is confounded by the fact that both diseases are simultaneously risk factors and consequences of each other. Finally, we chose not to perform a meta-regression of stroke due to the paucity of data on acute cerebrovascular events after CAP.

5. Future Directions {#sec5-jcm-09-00414}
====================

Despite the apparent reduction in the event rate, the absolute burden of CV disease means there is clearly room for improvement. Hence, from a health system perspective, CV morbidity and mortality after CAP highlight the pressing need for (1) acquiring a better understanding of the pathophysiologic mediators that lead to acute CV events, (2) conducting well-designed randomized clinical trials to assess the effect of targeted drug interventions (e.g., statins) on acute CV outcomes in CAP patients, and (3) implementing a risk stratification model to ameliorate the long-term prognosis of these patients. Finally, and despite common features shared by myocardial infarction, heart failure, arrhythmias, and stroke, gaining deeper insight into the interaction between each event and CAP could prove useful in tailoring preventative and therapeutic strategies at a patient level.

The following are available online at <https://www.mdpi.com/2077-0383/9/2/414/s1>. Table S1: PRISMA checklist; Table S2: Detailed characteristics of included studies; File S1: Funnel plot and Egger's test for included studies of (a) overall cardiac complications, (b) ACS, (c) heart failure, (d) arrhythmias and (e) stroke after CAP.
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###### 

Forest plots of incident overall cardiac complications after community-acquired pneumonia. (**A**) Inpatients (**B**) Low-risk inpatients. (**C**) High-risk inpatients. CI: confidence interval.

![](jcm-09-00414-g002a)

![](jcm-09-00414-g002b)

###### 

Forest plots of incident acute coronary syndromes (ACS) after community-acquired pneumonia. (**A**) Inpatients (**B**) Low-risk inpatients (**C**) High-risk inpatients (**D**) Outpatients. CI: confidence interval.
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###### 

Forest plots of incident heart failure after community-acquired pneumonia. (**A**) Inpatients (**B**) Low-risk inpatients (**C**) High-risk patients (**D**) Outpatients. CI: confidence interval.
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###### 

Forest plots of incident arrhythmias after community-acquired pneumonia. (**A**) Inpatients (**B**) High-risk inpatients (**C**) Outpatients. CI: confidence interval.
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![Forest plot of incident stroke of inpatients after community-acquired pneumonia. CI: confidence interval.](jcm-09-00414-g006){#jcm-09-00414-f006}

###### 

Meta-regression for (**A**) overall cardiac complications, (**B**) acute coronary syndromes ACS, (**C**) heart failure and (**D**) arrhythmias after community-acquired pneumonia, moderated by study year. Circle size is proportional to study sample size.
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jcm-09-00414-t001_Table 1

###### 

Characteristics of included studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \-                                                Year   Country              Study Type       Setting                               *n*        CV Events ^a^\   ACS ^b^\   Heart Failure\   Stroke ^c^\   Arrhythmias ^d^\
                                                                                                                                                  (%)              (%)        (%)              (%)           (%)
  ------------------------------------------------- ------ -------------------- ---------------- ------------------------------------- ---------- ---------------- ---------- ---------------- ------------- ------------------
  Allen et al. \[[@B28-jcm-09-00414]\]              1984   Zambia               Retrospective\   Inpatients                            502        \-               \-         \-               \-            0.40
                                                                                single center                                                                                                                

  Esposito et al. \[[@B29-jcm-09-00414]\]           1984   USA                  Prospective\     Inpatients                            38         \-               \-         7.9              \-            \-
                                                                                single center                                                                                                                

  Marrie et al. \[[@B30-jcm-09-00414]\]             1989   Canada               Prospective\     Inpatients                            583        \-               \-         11               \-            \-
                                                                                single center                                                                                                                

  Ortqvist et al. \[[@B31-jcm-09-00414]\]           1990   Sweden               Prospective,\    Inpatients                            277        13               \-         \-               \-            \-
                                                                                single center                                                                                                                

  Venkatesan et al. \[[@B32-jcm-09-00414]\]         1990   UK                   Prospective\     Inpatients                            73         \-               \-         \-               \-            11
                                                                                single center                                                                                                                

  Fine et al. \[[@B33-jcm-09-00414]\]               1990   USA                  Prospective\     Low-risk ^e^ inpatients Outpatients   170        \-               0.6        \-               \-            0.6
                                                                                single center                                                                                                                

  Woodhead et al. \[[@B34-jcm-09-00414]\]           1992   UK                   Retrospective\   High-risk ^f^ inpatients              72         \-               \-         \-               \-            23
                                                                                multicenter                                                                                                                  

  Leroy et al. \[[@B35-jcm-09-00414]\]              1995   France               Retrospective\   High-risk ^f^ inpatients              299        2.3              \-         \-               \-            \-
                                                                                single center                                                                                                                

  Janssens et al. \[[@B36-jcm-09-00414]\]           1995   Switzerland          Prospective,\    Inpatients                            99         \-               \-         33               \-            \-
                                                                                single center                                                                                                                

  Musher et al. \[[@B37-jcm-09-00414]\]             2000   USA                  Prospective\     Inpatients                            100        \-               \-         4.0              \-            \-
                                                                                single center                                                                                                                

  Férnandez-Sabé et al. \[[@B38-jcm-09-00414]\]     2003   Spain                Prospective\     Inpatients                            1474       \-               \-         7.2              \-            \-
                                                                                single center                                                                                                                

  Fine et al. \[[@B39-jcm-09-00414]\]               2003   USA                  Prospective\     Inpatients                            608        22               \-         \-               \-            \-
                                                                                multicenter                                                                                                                  

  Martínez-Moragón et al. \[[@B40-jcm-09-00414]\]   2004   Spain                Prospective\     Inpatients                            91         5.0              \-         \-               \-            \-
                                                                                single-center                                                                                                                

  Menéndez et al. \[[@B41-jcm-09-00414]\]           2004   Spain                Prospective\     Low-risk ^e^ inpatients               1424       \-               \-         8.7              \-            \-
                                                                                multicenter                                                                                                                  

  Querol-Ribelles et al. \[[@B42-jcm-09-00414]\]    2005   Spain                Prospective\     Low-risk ^e^ inpatients               459        \-               \-         8.6              \-            \-
                                                                                single-center                                                                                                                

  Díaz et al. \[[@B43-jcm-09-00414]\]               2005   Chile                Prospective\     High-risk ^f^ inpatients              113        \-               \-         24               \-            15
                                                                                Single-center                                                                                                                

  Marrie et al. \[[@B44-jcm-09-00414]\]             2005   Canada               Prospective\     Low-risk ^e^ inpatients               586        \-               0.3        1.4              \-            \-
                                                                                single center                                                                                                                

  McAlister et al. \[[@B45-jcm-09-00414]\]          2005   Canada               Prospective\     Low-risk ^e^ inpatients               2471       5.9              \-         \-               \-            \-
                                                                                multicenter                                                                                                                  

  O'Meara et al. \[[@B46-jcm-09-00414]\]            2005   USA                  Prospective\     Inpatients                            582        24               \-         \-               \-            \-
                                                                                multicenter                                                                                                                  

  Musher et al. \[[@B47-jcm-09-00414]\]             2007   USA                  Retrospective\   Inpatients ^g^                        170        19               7          15               \-            6
                                                                                single-center                                                                                                                

  Becker et al. \[[@B48-jcm-09-00414]\]             2007   Canada               Retrospective\   Inpatients                            391        17               8          12               \-            3
                                                                                multicenter                                                                                                                  

  Ramirez et al. \[[@B49-jcm-09-00414]\]            2008   Spain                Retrospective\   Inpatients                            500        \-               5.8        \-               \-            \-
                                                                                single-center                                                                                                                

  Cabré et al. \[[@B50-jcm-09-00414]\]              2008   Spain                Prospective\     Inpatients                            117        \-               0.9        12               \-            4.4
                                                                                single-center                                                                                                                

  Corrales-Medina et al. \[[@B51-jcm-09-00414]\]    2009   USA                  Retrospective\   Inpatients                            206        \-               11         \-               \-            \-
                                                                                single-center                                                                                                                

  Mandal et al. \[[@B52-jcm-09-00414]\]             2011   Scotland             Retrospective\   Inpatients                            5034       \-               5.0        \-               2.2           9.3
                                                                                multicenter                                                                                                                  

  Perry et al. \[[@B53-jcm-09-00414]\]              2011   USA                  Retrospective\   Inpatients                            50119      \-               2.3        9.1              0.1           8.4
                                                                                multicenter                                                                                                                  

  Corrales-Medina et al. \[[@B54-jcm-09-00414]\]    2012   USA and Canada       Prospective\     Inpatients\                           1343\      27\              3.6\       67\              \-            22\
                                                                                multicenter      Outpatients                           944        2.1              0          65                             35

  Viasus et al. \[[@B55-jcm-09-00414]\]             2013   Spain                Prospective\     Low-risk inpatients\                  1621^h^\   3.0\             0.76       3.0              \-            5.1
                                                                                single center    High-risk inpatients ^f^              2300       11.6                                                       

  Griffin et al. \[[@B56-jcm-09-00414]\]            2013   13 countries         Retrospective\   Inpatients                            3068       14               1.3        2.1              \-            3.6
                                                                                multicenter                                                                                                                  

  Aliberti et al. \[[@B57-jcm-09-00414]\]           2015   Italy, Switzerland   Retrospective\   Inpatients                            905        \-               2.3        3.7              1.1           19
                                                                                multicenter                                                                                                                  

  Cangemi et al. \[[@B58-jcm-09-00414]\]            2015   Italy                Prospective,\    Inpatients                            301        18               11         \-               \-            10
                                                                                single center                                                                                                                

  Corrales-Medina et al. \[[@B59-jcm-09-00414]\]    2015   USA                  Retrospective\   Inpatients                            508        11               \-         \-               \-            \-
                                                                                multicenter                                                                                                                  

  Corrales-Medina et al. \[[@B59-jcm-09-00414]\]    2015   USA                  Retrospective\   Inpatients                            426        0.90             \-         \-               \-            \-
                                                                                multicenter                                                                                                                  

  Chen et al. \[[@B60-jcm-09-00414]\]               2015   Taiwan               Single-center\   Inpatients                            746        \-               2.3        \-               \-            \-
                                                                                retrospective                                                                                                                

  Violi et al. \[[@B61-jcm-09-00414]\]              2017   Italy, Canada        Prospective\     Low-risk inpatients\                  355 ^h^\   12\              8.4        24               0.1           9.2
                                                                                multicenter      High-risk inpatients ^f^              827        41                                                         

  Eurich et al. \[[@B62-jcm-09-00414]\]             2017   Canada               Prospective\     Inpatients\                           4988       \-               \-         12               \-            \-
                                                                                multicenter      Outpatients                                                                                                 

  Cilli et al. \[[@B63-jcm-09-00414]\]              2018   Turkey               Retrospective\   High-risk ^f^ inpatients              373        15               0.54       2.9              \-            12
                                                                                multicenter                                                                                                                  

  Postma et al. \[[@B64-jcm-09-00414]\]             2019   Netherlands          Retrospective\   Inpatients                            2107       7.9              0.7        4.8              \-            2.5
                                                                                multicenter                                                                                                                  

  Pieralli et al. \[[@B65-jcm-09-00414]\]           2019   Italy                Retrospective\   Inpatients                            468        \-               \-         \-               \-            10.3
                                                                                single-center                                                                                                                

  Cangemi et al. \[[@B66-jcm-09-00414]\]            2019   Italy                Prospective\     Inpatients                            545        \-               \-         \-               \-            9.5
                                                                                single center                                                                                                                
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Cardiovascular (CV) events: congestive heart failure, atrial fibrillation, severe angina or myocardial infarction or stroke \[[@B31-jcm-09-00414]\]; acute coronary or ventricular insufficiency \[[@B35-jcm-09-00414]\]; cardiovascular complications likely to necessitate continued hospitalization \[[@B39-jcm-09-00414]\]; cardiac complications without further specification \[[@B40-jcm-09-00414]\]; acute coronary syndrome and/or heart failure \[[@B45-jcm-09-00414]\]; myocardial infarction, angina pectoris, revascularization by angioplasty/coronary artery bypass graft (CABG) or death secondary to coronary heart disease, cerebrovascular accident, congestive heart insufficiency or claudication \[[@B46-jcm-09-00414]\]; myocardial infarction, atrial fibrillation or ventricular tachycardia or incident heart failure \[[@B47-jcm-09-00414]\]; myocardial infarction, atrial fibrillation, congestive heart failure or stroke \[[@B48-jcm-09-00414]\]; new or worsening heart failure, new or worsening arrhythmias or myocardial infarction \[[@B54-jcm-09-00414]\]; new-onset or worsening cardiac arrhythmias, new-onset or worsening congestive heart failure or myocardial infarction \[[@B55-jcm-09-00414]\]; acute pulmonary edema, new onset cardiac arrhythmia, exacerbation of a preexisting arrhythmia, or myocardial infarction \[[@B56-jcm-09-00414]\]; acute myocardial infarction, acute cardiogenic pulmonary edema, new arrhythmia, acute worsening of a long-term arrhythmia, cerebrovascular accident or pulmonary embolism \[[@B57-jcm-09-00414]\];cardiovascular death, non-fatal myocardial infarction or stroke \[[@B58-jcm-09-00414]\]; non-ST elevation myocardial infarction or ST elevation myocardial infarction, stroke, new episode of atrial fibrillation or deep venous thrombosis and/or pulmonary embolism, new or worsening HF or cardiovascular death \[[@B61-jcm-09-00414]\] new onset or worsening arrhythmia, new onset or worsening heart failure or myocardial infarction \[[@B63-jcm-09-00414]\]: new or worsening arrhythmia, heart failure or myocardial ischemia \[[@B64-jcm-09-00414]\]. ^b^ Acute coronary syndromes (ACS): myocardial infarction \[[@B33-jcm-09-00414],[@B37-jcm-09-00414],[@B39-jcm-09-00414],[@B47-jcm-09-00414],[@B48-jcm-09-00414],[@B49-jcm-09-00414],[@B53-jcm-09-00414],[@B54-jcm-09-00414],[@B55-jcm-09-00414],[@B56-jcm-09-00414],[@B57-jcm-09-00414],[@B58-jcm-09-00414],[@B60-jcm-09-00414],[@B61-jcm-09-00414],[@B63-jcm-09-00414],[@B64-jcm-09-00414]\]; unstable angina \[[@B44-jcm-09-00414]\]; acute coronary syndrome \[[@B50-jcm-09-00414],[@B51-jcm-09-00414]\]; acute coronary syndrome or ST segment elevation myocardial infarction \[[@B52-jcm-09-00414]\]. ^c^ Stroke: new-onset neurological deficit \[[@B53-jcm-09-00414]\]; unspecified stroke \[[@B52-jcm-09-00414],[@B61-jcm-09-00414]\]; cerebrovascular accident \[[@B57-jcm-09-00414]\]. ^d^ Arrhythmias: incident atrial fibrillation \[[@B28-jcm-09-00414],[@B32-jcm-09-00414],[@B33-jcm-09-00414],[@B48-jcm-09-00414],[@B49-jcm-09-00414],[@B50-jcm-09-00414],[@B52-jcm-09-00414],[@B53-jcm-09-00414],[@B54-jcm-09-00414],[@B55-jcm-09-00414],[@B56-jcm-09-00414],[@B57-jcm-09-00414],[@B58-jcm-09-00414],[@B61-jcm-09-00414],[@B64-jcm-09-00414],[@B65-jcm-09-00414],[@B66-jcm-09-00414]\]; cardiac dysrhythmias/arrhythmias \[[@B34-jcm-09-00414],[@B43-jcm-09-00414]\]; atrial flutter or fibrillation, and ventricular tachycardia, but excluding terminal arrhythmias \[[@B47-jcm-09-00414]\]. ^e^ Inpatients without severe vital signs or metabolic abnormalities, altered mental status, suppurative complications or coexisting medical conditions requiring hospitalization \[[@B33-jcm-09-00414]\]; inpatients who survived the first 48 h of hospitalization \[[@B41-jcm-09-00414]\], inpatients not initially admitted to the intensive care unit \[[@B42-jcm-09-00414],[@B45-jcm-09-00414]\]; inpatients with pneumonia severity index (PSI) risk classes I--II \[[@B44-jcm-09-00414]\]. ^f^ Inpatients admitted to the intensive care unit (ICU). ^g^ For ACS, patients from Musher et al. (2007) \[[@B47-jcm-09-00414]\] were included in Corrales-Medina et al. (2009) \[[@B51-jcm-09-00414]\]. ^h^ Data available for low-risk or high-risk patients if overall cardiac events are considered.

jcm-09-00414-t002_Table 2

###### 

Included studies presenting independent predictors of cardiovascular (CV) events after community-acquired pneumonia (CAP).

  ------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                           Year          *n* with Event     Outcome                         Independent Predictors
  ------------------------------------------------ ------------- ------------------ ------------------------------- ------------------------------
  Corrales-Medina et al. \[[@B51-jcm-09-00414]\]   2009          206                ACS                             Age\
                                                                                                                    Congestive heart failure

  Mandal et al. \[[@B52-jcm-09-00414]\]            2011          252                ACS                             Age ≥ 65\
                                                                                                                    Previous MI\
                                                                                                                    COPD\
                                                                                                                    Chronic kidney disease

  468                                              Arrhythmias   Age\                                               
                                                                 Previous MI\                                       
                                                                 Diabetes                                           

  111                                              Stroke        Prior stroke\                                      
                                                                 COPD                                               

  Perry et al. \[[@B53-jcm-09-00414]\]             2011          2002               CHF                             Age\
                                                                                                                    Admission to ICU\
                                                                                                                    Previous MI\
                                                                                                                    COPD Diabetes\
                                                                                                                    Chronic kidney disease\
                                                                                                                    Cancer

  2732                                             Arrhythmias   Age\                                               
                                                                 Admission to ICU                                   

  Corrales-Medina et al. \[[@B54-jcm-09-00414]\]   2012          378                Overall cardiac complications   Age\
                                                                                                                    Nursing home\
                                                                                                                    Hypertension\
                                                                                                                    Previous CAD\
                                                                                                                    Previous arrhythmias\
                                                                                                                    Previous CHF\
                                                                                                                    RR ≥ 30/min\
                                                                                                                    pH \< 7.35\
                                                                                                                    BUN ≥ 30 mg/dL\
                                                                                                                    Sodium \< 130 mmol/L\
                                                                                                                    Hematocrit \< 30%\
                                                                                                                    Pleural effusion\
                                                                                                                    Inpatient

  Viasus et al. \[[@B55-jcm-09-00414]\]            2013          315                Overall cardiac complications   Age ≥ 65\
                                                                                                                    Chronic heart disease\
                                                                                                                    Septic shock\
                                                                                                                    Tachycardia\
                                                                                                                    Albumin \< 3 g/dL\
                                                                                                                    Multilobar pneumonia\
                                                                                                                    Streptococcal pneumonia

  Griffin et al. \[[@B56-jcm-09-00414]\]           2013          376                Overall cardiac complications   Hyperlipidemia\
                                                                                                                    Statin therapy ^1^\
                                                                                                                    *Staphylococcus aureus*\
                                                                                                                    *Klebsiella pneumoniae*\
                                                                                                                    PSI

  Aliberti et al. \[[@B57-jcm-09-00414]\]          2015          21                 ACS                             Female sex\
                                                                                                                    Severe sepsis\
                                                                                                                    Liver disease

  Cangemi et al. \[[@B58-jcm-09-00414]\]           2015          55                 Overall cardiac complications   Age\
                                                                                                                    Hypertension\
                                                                                                                    Diabetes\
                                                                                                                    Baseline troponin

  Violi et al. \[[@B61-jcm-09-00414]\]             2017          308                Overall cardiac complications   Age\
                                                                                                                    CHF\
                                                                                                                    PSI

  Cilli et al. \[[@B63-jcm-09-00414]\]             2018          56                 Overall cardiac complications   Age\
                                                                                                                    Hypoalbuminemia\
                                                                                                                    Diuretic\
                                                                                                                    Vasopressor\
                                                                                                                    Haloperidol

  Postma et al. \[[@B64-jcm-09-00414]\]            2019          2107               Overall cardiac complications   Erythromycin use

  Pieralli et al. \[[@B65-jcm-09-00414]\]          2019          468                Atrial fibrillation             CURB-65 \> 2\
                                                                                                                    CHA~2~DS~2~-VASc \> 3

  Cangemi et al. \[[@B66-jcm-09-00414]\]           2019          545                Atrial fibrillation             Prior paroxysmal AF,\
                                                                                                                    Enlarged LAAi\
                                                                                                                    Left ventricular hypertrophy
  ------------------------------------------------------------------------------------------------------------------------------------------------

^1^ Protective effect. ACS: acute coronary syndrome; AF: atrial fibrillation; BUN: blood urea nitrogen; CAD: coronary artery disease; CHA~2~DS~2~-VASc: congestive heart failure, hypertension, age-doubled, diabetes, stroke-doubled, vascular disease, age, sex-category; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; CURB-65: confusion, urea, respiratory rate, blood urea nitrogen, age \> 65; ICU: intensive care unit; LAAi (left atrial area index); MI: myocardial infarction; PSI: pneumonia severity index; RR: respiratory rate.

jcm-09-00414-t003_Table 3

###### 

Association of CV events and mortality after CAP.

  Study                                                Year                                  Event                           Mortality     Measure of Risk
  ---------------------------------------------------- ------------------------------------- ------------------------------- ------------- --------------------------------------
  **Mandal et al.** \[[@B52-jcm-09-00414]\]            2001                                  Stroke                          90-day        OR 1.79 (1.51--2.12), *p* \< 0.0001
  MI                                                   OR 2.93 (1.60--2.33), *p* \< 0.0001                                                 
  AF                                                   OR 1.39 (1.65--2.19), *p* \< 0.0001                                                 
  **Corrales-Medina et al.** \[[@B54-jcm-09-00414]\]   2012                                  Overall cardiac complications   30-day        OR 1.6 (1.04--2.5), *p* \< 0.001
  **Viasus et al.** \[[@B55-jcm-09-00414]\]            2013                                  Overall cardiac complications   30-day        OR 2.18 (1.38--3.42)
  **Aliberti et al.** \[[@B57-jcm-09-00414]\]          2015                                  ACS                             In-hospital   OR 3.57 (1.32--9.69), *p* = 0.02
  Other events                                         OR 2.63 (1.43--4.84), *p* = NS                                                      
  **Cangemi et al.** \[[@B58-jcm-09-00414]\]           2015                                  Overall cardiac complications   6-60 months   OR 1.759 (1.099--2.816), *p* = 0.019
  **Violi et al.** \[[@B61-jcm-09-00414]\]             2017                                  Overall cardiac complications   30-day        HR 5.49, *p* \< 0.001
  **Cilli et al.** \[[@B63-jcm-09-00414]\]             2018                                  Overall cardiac complications   In-hospital   OR 2.18 (1.03--4.61), *p* = 0.04
  90-day                                               NS                                                                                  

ACS: acute coronary syndrome; AF: atrial fibrillation; MI: myocardial infarction; NS: not significant; OR: odds-ratio; HR: hazard-ratio.
